Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 404-414

  Andreu, Nuria ^a   Fletcher, Taryn ^a   Krishnan, Nitya ^a   Wiles, Siouxsie ^a,b   Robertson, Brian D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bacterial luciferase; Drug screening assay; Firefly luciferase; Tuberculosis

Indexed keywords

CHLORAMPHENICOL; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; RESAZURIN; RIFAMPICIN; STREPTOMYCIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BIOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TIME;

ANTITUBERCULAR AGENTS; COSTS AND COST ANALYSIS; GENES, REPORTER; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84855849464     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr472     Document Type: Article

References (34)

1. WHO. Global Tuberculosis Control 2010. Geneva: WHO Press, 2010.
2. Orme I. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 2001; 45: 1943-6.
3. Primm TP, Franzblau SG. Recent advances in methodologies for the discovery of antimycobacterial drugs. Curr Bioact Compd 2007; 3: 201-8.
4. Caviedes L, Delgado J, Gilman RH. Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 1873-4.
5. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
6. Palomino J-C, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2.
7. Gruppo V, Johnson CM, Marietta KS et al. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 1245-50.
8. Changsen C, Franzblau SG, Palittapongarnpim P. Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob Agents Chemother 2003; 47: 3682-7.
9. Srivastava R, Deb DK, Srivastava KK et al. Green fluorescent protein as a reporter in rapid screening of antituberculosis compounds in vitro and in macrophages. Biochem Biophys Res Commun 1998; 253: 431-6.
10. Deb DK, Srivastava KK, Srivastava R et al. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem Biophys Res Commun 2000; 279: 457-61.
11. Arain T, Resconi A, Singh D et al. Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Antimicrob Agents Chemother 1996; 40: 1542-4.
12. Heuts F, Carow B, Wigzell H et al. Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect 2009; 11: 1114-21.
13. Mortin LI, Li T, Van Praagh ADG et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007; 51: 1787-94.
14. Kadurugamuwa JL, Modi K, Yu J et al. Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice. Infect Immun 2005; 73: 3878-87.
15. Kadurugamuwa JL, Modi K, Yu J et al. Noninvasive monitoring of pneumococcal meningitis and evaluation of treatment efficacy in an experimental mouse model. Mol Imaging 2005; 4: 137-42.
16. Cho JS, Zussman J, Donegan NP et al. Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections. J Invest Dermatol 2011; 131: 907-15.
17. Hickey M, Arain T, Shawar R et al. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 1996; 40: 400-7.
18. Andreu N, Zelmer A, Fletcher T et al. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS ONE 2010; 5: e10777.
19. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
20. Rastogi N, Potar M-C, David HL. Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J774: ultrastructure and drug-susceptibility studies. Curr Microbiol 1987; 16: 14.
21. Skinner PS, Furney SK, Jacobs MR et al. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob Agents Chemother 1994; 38: 2557-63.
22. Wright EL, Quenelle DC, Suling WJ et al. Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob Agents Chemother 1996; 40: 2206-8.
23. Motulsky HJ, Christopoulos A. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. San Diego, CA: GraphPad Software Inc., 2003.
24. Streptomycin. Tuberculosis (Edinb) 2008; 88: 162-3.
25. Isoniazid. Tuberculosis (Edinb) 2008; 88: 112-6.
26. Eklund D, Welin A, Schon T et al. Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis. Clin Vaccine Immunol 2010; 17: 513-7.
27. Cho SH, Warit S, Wan B et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1380-5.
28. Turner DJ, Hoyle SL, Snewin VA et al. An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis. Microbiology 2002; 148: 2929-36.
29. Arain TM, Resconi AE, Hickey MJ et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 1996; 40: 1536-41.
30. Cooksey RC, Morlock GP, Beggs M et al. Bioluminescence method to evaluate antimicrobial agents against Mycobacterium avium. Antimicrob Agents Chemother 1995; 39: 754-6.
31. Cooksey RC, Crawford JT, Jacobs WR Jr et al. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother 1993; 37: 1348-52.
32. Zhang T, Bishai WR, Grosset JH et al. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother 2010; 54: 2806-13.
33. Shawar RM, Humble DJ, Van Dalfsen JM et al. Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare. Antimicrob Agents Chemother 1997; 41: 570-4.
34. Sato K, Tomioka H, Sano C et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 2003; 52: 199-203.